Welcome to our dedicated page for Sellas Life Sciences Group SEC filings (Ticker: SLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SELLAS Life Sciences Group, Inc. filings document a Nasdaq-listed clinical biopharmaceutical company developing cancer therapeutics, including GPS and SLS009 programs in acute myeloid leukemia. Form 8-K reports cover operating results, financial condition, corporate updates, clinical program disclosures, and material agreements.
The filing record also includes capital-structure disclosures for common stock and warrants, warrant inducement agreements and exercise proceeds, share-count updates, and facility-related agreements. Proxy materials document annual meeting proposals, stockholder voting procedures, and governance matters.
SELLAS Life Sciences Group, Inc. entered into a warrant inducement agreement with an existing warrant holder to raise cash and restructure its warrant profile. The holder agreed to cash exercise 19,685,040 shares of common stock at $1.20 per share, providing the company with approximately $23.6 million in gross proceeds before fees. In return, SELLAS will issue new inducement warrants to purchase up to 19,685,040 additional shares at an exercise price of $1.88 per share, exercisable immediately and expiring in five and a half years.
The company engaged A.G.P./Alliance Global Partners and Maxim Group as financial advisors and will pay a fee equal to 6.5% of the gross proceeds, plus up to $60,000 in legal expense reimbursement. For 90 days, SELLAS agreed to limit new equity and registration activity with specified exceptions, and for 12 months it is barred from entering variable rate transactions, equity lines, or at-the-market offerings. The new inducement warrants and their underlying shares are being issued in a private, unregistered offering under Section 4(a)(2) of the Securities Act.
Sellas Life Sciences Group, Inc. (SLS) received a Schedule 13G/A showing that Anson Funds Management LP and related Anson entities and principals collectively report beneficial ownership of 5,225,948 shares, representing 4.9% of the outstanding common stock on a fully diluted basis that includes shares underlying warrants. The reported share count uses 99,777,487 outstanding shares plus 4,950,948 shares issuable upon exercise of warrants to reach a 104,728,435 share denominator. The filing states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control, and that exercise of warrants is subject to beneficial ownership limitations.
SELLAS Life Sciences Group, Inc. has filed a Form S-8 to register 800,000 additional shares of common stock for issuance under its Amended and Restated 2021 Employee Stock Purchase Plan. The increase of 800,000 shares was approved by the companys stockholders on June 17, 2025. The filing incorporates prior Form S-8 information by reference and includes customary legal and accounting consents and opinions.
SELLAS Life Sciences Group disclosed that it has issued a press release announcing its financial results for the quarter ended June 30, 2025 and providing a corporate update. The press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated by reference, but the company states the press release is furnished and not deemed "filed" for purposes of certain securities laws.
The Form identifies the registrant and trading symbol SLS on Nasdaq, provides principal office contact details, and is signed by John T. Burns, Senior Vice President and Chief Financial Officer. The 8-K itself does not present the underlying financial figures; readers must consult Exhibit 99.1 for complete results and the corporate update.
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company focused on immunotherapies for hematologic and solid tumors. For the six months ended June 30, 2025, the company reported a net loss of $12.4 million, used $16.4 million of cash in operations, and had $25.3 million of cash and cash equivalents with an accumulated deficit of $260.5 million. Management states these resources are not expected to be sufficient for at least the next 12 months, and substantial doubt about going concern exists.
Clinically, the company reported positive developments: the REGAL Phase 3 GPS study's independent data monitoring committee recommended continuation after its interim review and the final analysis will occur at 80 events. Separately, SLS009 met primary endpoints in a Phase 2 study with an overall response rate of 33% (40% at the 30 mg BIW dose) and particularly strong responses in patients with ASXL1 mutations (50% ORR); the FDA provided guidance to advance a randomized first-line trial. Recent financing included a January 2025 registered direct offering with net proceeds of approximately $23.1 million.
The Form 8-K filed by SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) discloses the voting results from the Company’s Annual Meeting held on June 17, 2025. Of the 94.5 million shares outstanding, 61.3 million (64.85%) were present or represented by proxy.
- Board elections: Class III directors Angelos M. Stergiou and John Varian were re-elected, receiving 83% and 84% of votes cast, respectively, excluding broker non-votes.
- Auditor ratification: Stockholders confirmed Baker Tilly US, LLP as independent auditor for FY 2025 with a strong 86.9% “For” vote.
- Equity plan amendment: An increase of 800,000 shares under the 2021 Employee Stock Purchase Plan was approved (66% “For”).
- Say-on-pay: The advisory resolution on executive compensation passed with 69% support.
- Say-on-frequency: A plurality of holders (74%) preferred an annual vote on executive compensation.
- Adjournment authority: Shareholders granted the Board discretion to adjourn the meeting if additional proxy solicitation were needed.
No other matters were presented, and no financial performance data or strategic transactions were reported in this filing.